Close Menu

Safety and Efficacy KollaGen II-xs: A 60-day Clinical Trial


Objectives: The present single-center clinical trial investigated the safety and efficacy of an avian sternal collagen type II hydrolysate, KollaGen II-xsTM.

Methods: A goniometer was used to measure the range of motion, a pain scale (Borg) was applied to subjectively percept the pain, and a properly calibrated sphygmomanometer was utilized to evaluate muscle strength

Results: The results indicated that administration of 2000 mg/day of collagen type II hydrolysate for 60 days improved essential symptoms in individuals suffering from joint diseases, including range of motion, general pain, and muscle strength. No adverse effects were observed during the trial.

Discussion: The results support the view that collagen type II hydrolysate may be administered to patients suffering from joint diseases. These data encourage its use for patients suffering from degenerative joint diseases, including cartilage injuries, connective tissue disorders, polychondritis, joint defects, osteoarthritis, and rheumatoid arthritis.

12 Aug, 2016
PDF Attachment: 
e-Published: 12 Aug, 2016


Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.

Top of Page